enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Dapagliflozin - Wikipedia

    en.wikipedia.org/wiki/Dapagliflozin

    Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .

  3. FDA approves new pain medication as an alternative to ... - AOL

    www.aol.com/news/fda-approves-pain-medication...

    For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

  4. FDA approves first new type of pain medication in 25 years - AOL

    www.aol.com/news/fda-approves-first-type-pain...

    A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx. FDA approves first new type of ...

  5. Dapagliflozin/metformin - Wikipedia

    en.wikipedia.org/wiki/Dapagliflozin/metformin

    To lessen the risk of developing ketoacidosis (a serious condition in which the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medicines to recommend they be stopped temporarily before scheduled surgery. Canagliflozin, dapagliflozin ...

  6. FDA approves new type of non-opioid pain medication, 1st of ...

    www.aol.com/news/fda-approves-type-non-opioid...

    The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...

  7. Suzetrigine - Wikipedia

    en.wikipedia.org/wiki/Suzetrigine

    Suzetrigine, sold under the brand name Journavx, is a medication used for the management of pain. [1] [2] It is a non-opioid, small-molecule analgesic that works as a selective inhibitor of Na v 1.8-dependent pain-signaling pathways in the peripheral nervous system, [3] [4] avoiding the addictive potential of opioids.

  8. FDA approves painkiller designed to eliminate the risk of ...

    www.aol.com/news/fda-approves-painkiller...

    The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids, which are often available as generics for $1 or less.

  9. SGLT2 inhibitor - Wikipedia

    en.wikipedia.org/wiki/SGLT2_inhibitor

    Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.